Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
about
New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological MalignanciesBeyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-LactamasesRandomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coliComparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.Mechanisms of antimicrobial resistance in Gram-negative bacilli.A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing EnterobacteriaceaeClinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrosβ-lactam/β-lactamase inhibitor combinations: from then to now.Population analysis of Escherichia coli isolates with discordant resistance levels by piperacillin-tazobactam broth microdilution and agar dilution testing.Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis.Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: A systematic review.Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae.Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project.Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae.Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-LactamasesPiperacillin-tazobactam as alternative to carbapenems for ICU patients.Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis.Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review.Point-Counterpoint: Piperacillin-tazobactam should be used to treat infections with ESBL-positive organisms.Nosocomial spontaneous bacterial peritonitis: discussing a specific infection treatment algorithm.[Bacterial sepsis : Diagnostics and calculated antibiotic therapy].Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Treatment of extended-spectrum β-lactamase-producing (ESBLs) infections: what have we learned until now?
P2860
Q26799580-FBEAEBE6-724C-4012-8340-CFC0A44C1451Q28249617-6B65E9FB-0642-4DDA-93B9-749DAF0C34D9Q33776486-9CE5E115-C4BC-4BB7-822C-A14078ED7855Q35552650-72C11FF4-DFE5-4329-89DB-D380889E23DBQ35935319-6AE786F7-46B9-4DAE-9CBE-31F65FDBD9ACQ37023191-BA865481-40DB-4AD6-A4CE-E3FD71F3177FQ37612207-0EB8CE29-136C-4648-AFB7-AB393F9CB37FQ38264182-5A17E313-897F-4413-B2D8-3CCB5E692D26Q38324520-C9544CE4-34CD-44BD-9B16-209627626261Q38511551-ED259949-FB4F-4342-8611-04B45A0DDE9DQ38739545-AAA606B5-D284-47F7-8824-F1D2EDE6CFD8Q38981397-1896B80B-B1AE-49E9-B540-3EDD93C93B76Q39455604-4AA67F7D-8267-45A9-973A-4B5FAF10178FQ40044307-6729CBC6-BC39-4D26-8587-D9C2812E964CQ40202149-CF82F417-705B-4F3B-B83E-0A997033185CQ40922179-8F2D4D1F-3CD5-4A0F-8195-B97C238EF512Q41004466-6F955BE8-A78F-4BCE-BD2E-0CE967675F17Q41217004-2374B7A4-F3B9-42D9-9DBF-B323A3596430Q42358846-439B8337-41D6-427A-BC91-87B39521B26CQ45711115-03225F9D-9255-481C-B850-9176BE70ED1BQ47099854-9139E628-023C-480B-BC14-D50FC868718BQ47312597-E2F6F142-DD4E-4AC6-9190-9538E76043B8Q47315442-805480D6-8107-4006-9C37-F1A4B7CEB388Q48258925-C4EF7057-3025-4651-8D98-FF09530409A7Q49589601-BF5B93FA-9ED2-436A-8772-7D0981E7D25AQ52695014-AFB91DC6-2ED9-4FDA-A647-FCFE1237E680Q58694612-7BD7BF58-DD2E-4D78-9B90-E3DA8E9C53A1
P2860
Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Impact of the MIC of piperacil ...... se-producing Escherichia coli.
@en
type
label
Impact of the MIC of piperacil ...... se-producing Escherichia coli.
@en
prefLabel
Impact of the MIC of piperacil ...... se-producing Escherichia coli.
@en
P2093
P2860
P50
P356
P1476
Impact of the MIC of piperacil ...... ase-producing Escherichia coli
@en
P2093
ESBL-REIPI/GEIH Group
Miguel Angel Muniain
Pilar Retamar
P2860
P304
P356
10.1128/AAC.00135-13
P407
P577
2013-04-22T00:00:00Z